Perimeter Medical Imaging AI, Inc. – a commercial-stage medical technology company – announced that patient randomization is underway at Mayo Clinic in Florida, the most recent clinical site to be initiated as part of an ongoing multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software.
Dr. Sarah Butler, Perimeter’s Vice President, Clinical and Medical Affairs stated, “Patient recruitment and randomization is underway at the Mayo Clinic in Florida, which is one of the sites where we are studying the combination of the Perimeter B-Series medical imaging platform with artificial intelligence software. Combining high-resolution optical coherence tomography with AI algorithms can potentially help surgeons better identify regions of interest during breast conserving surgeries, with the aim of improving patient outcomes and reducing healthcare costs.”
Also Read: Klick Health Launches First ChatGPT Plugin for Life Sciences Industry in US
Adrian Mendes, Perimeter’s Chief Executive Officer stated, “We are pleased that we continue to advance our ongoing pivotal clinical trial, supporting our goal to expedite the development of our next-gen AI technology. With its potential to become the new standard for specimen imaging technology during breast conservation surgery, our hope is that the data generated from this study will support the commercialization of Perimeter B-Series.”
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month.
SOURCE: PRNewswire
